Coherus Oncology (CHRS) Return on Capital Employed (2014 - 2026)
Coherus Oncology (CHRS) reported Return on Capital Employed of 132.34% for Q1 2026, down 1778.0% on a YoY basis from 7.89% in Q1 2025, and down 80.5% sequentially from 73.32% in Q4 2025.
Coherus Oncology (CHRS) Return on Capital Employed (2014 - 2026) Analysis & Trends
Coherus Oncology (CHRS) has 13 years of Return on Capital Employed data on file, last reported at 132.34% in Q1 2026.
- For the quarter ending Q1 2026, Return on Capital Employed fell 1778.0% year-over-year to 132.34%; the trailing twelve-month figure through Mar 2026 stood at 132.34% (down 1778.0% YoY), and the FY2025 full-year result was 85.02%, down 706.0% from the prior year.
- Return on Capital Employed declined to 132.34% in Q1 2026, from 73.32% in the prior quarter.
- In the past five years, Return on Capital Employed ranged from a high of 36.76% in Q1 2022 to a low of 170.91% in Q3 2025.
- A 5-year average of 89.88% and a median of 76.58% in 2023 frame the typical range for Return on Capital Employed.
- Peak annual rise in Return on Capital Employed reached 2971 bps in 2025, while the deepest fall reached 9509 bps in 2025.
- Tracing CHRS's Return on Capital Employed over 5 years: stood at 68.1% in 2022, then retreated by 9 bps to 73.91% in 2023, then sank by 39 bps to 103.03% in 2024, then climbed by 29 bps to 73.32% in 2025, then sank by 81 bps to 132.34% in 2026.
- Business Quant data shows CHRS's Return on Capital Employed at 132.34% in Q1 2026, 73.32% in Q4 2025, and 170.91% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -31.80% |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 10.46% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -68.47% |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 21.10% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 10.19% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -68.84% |
| 10 | Coherus Oncology | 195.05 Mn | 28.00 Mn | 8.50 Mn | -132.34% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -132.34% |
| Dec 31, 2025 | -73.32% |
| Sep 30, 2025 | -170.91% |
| Jun 30, 2025 | -129.32% |
| Mar 31, 2025 | -114.57% |
| Dec 31, 2024 | -103.03% |
| Sep 30, 2024 | -75.82% |
| Jun 30, 2024 | -81.31% |
| Mar 31, 2024 | -128.41% |
| Dec 31, 2023 | -73.91% |
| Sep 30, 2023 | -64.73% |
| Jun 30, 2023 | -87.87% |
| Mar 31, 2023 | -76.58% |
| Dec 31, 2022 | -68.10% |
| Sep 30, 2022 | -64.95% |
| Jun 30, 2022 | -45.99% |
| Mar 31, 2022 | -36.76% |
| Dec 31, 2021 | -48.40% |
| Sep 30, 2021 | -49.46% |
| Jun 30, 2021 | -32.93% |